This variation in the structure of the fusion protein, i.e., the various parts of the ABL and NUP214 molecules that are included in the fusion protein, probably led to a biological and clinical heterogeneity of ABL1-NUP214 AML. The gene discussed is ABL1; the disease is acute myeloid leukemia.